Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer

F. Andre, R. Nahta, R. Conforti, T. Boulet, M. Aziz, L. X.H. Yuan, F. Meslin, M. Spielmann, G. Tomasic, L. Pusztai, G. N. Hortobagyi, S. Michiels, S. Delaloge, F. J. Esteva

    Research output: Contribution to journalArticlepeer-review

    32 Citations (Scopus)

    Abstract

    Background: AKT phosphorylation is a critical step in the activation of growth factor receptors and can mediate tumor resistance to anthracyclines. We evaluated the expression patterns and predictive value of phosphorylated AKT (pAKT) in breast cancer tissues. Patients and methods: pAKT expression was assessed by immunohistochemistry in 823 tumors from patients with early breast cancer enrolled in two randomized trials. The distribution of pAKT expression was correlated with HER2 and epidermal growth factor receptor (EGFR) expression. The predictive value of pAKT for the efficacy of adjuvant chemotherapy was determined by test for interaction. Results: pAKT, EGFR, and HER2 were expressed in 119 of 781 (15%), 118 of 758 (16%), and 99 of 775 (13%) assessable tumors. Staining was positive for pAKT in 28 of 99 (28%) and 90 of 676 (13%) HER2+ and HER2- tumors (P < 0.001). pAKT was expressed in 15 of 94 (16%) and 75 of 563 (13%) HER2-/EGFR+ and HER2-/EGFR- tumors, respectively (P = 0.49). A positive staining for pAKT did not correlate with prognosis (P = 0.94), and did not predict the resistance to anthracyclines (test for interaction, P = 0.70). Conclusions: AKT phosphorylation is associated with HER2 expression but not EGFR expression in patients with early breast cancer. pAKT is not predictive for the efficacy of anthracycline-based adjuvant chemotherapy.

    Original languageEnglish
    Pages (from-to)315-320
    Number of pages6
    JournalAnnals of Oncology
    Volume19
    Issue number2
    DOIs
    Publication statusPublished - 1 Jan 2008

    Keywords

    • AKT
    • Breast cancer
    • EGFR
    • HER2

    Cite this